rasoul raesi

Dr. rasoul raesi


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HHHasan Hosseini
Hasan Hosseini
SHSina Heydari
Sina Heydari
KHKiavash Hushmandi
Kiavash Hushmandi
SDSalman Daneshi
Salman Daneshi
RRrasoul raesi
rasoul raesi
Though relatively rare, bone tumors significantly impact patient health and treatment outcomes. This systematic review analyzes the incidence, types, survival rates, and risk factors associated with bone tumors, including both benign and malignant forms. This systematic review was conducted using the keywords “bone tumors,” “epidemiology,” “benign bone tumors,” “malignant bone tumors,” “osteosarcoma,” “Ewing sarcoma,” “chondrosarcoma,” “risk factors,” and “survival” in electronic databases including PubMed, Scopus, Web of Science, and Google Scholar from 2000 to 2024. The search strategy was based on the PRISMA statement. Finally, 9 articles were selected for inclusion in the study. The systematic review highlights that primary bone tumors can be classified into benign and malignant types, with osteosarcoma being the most prevalent malignant form, particularly among adolescents and young adults. The epidemiology of bone tumors is influenced by factors such as age, gender, geographic location, and genetic predispositions. Recent advancements in imaging techniques have improved the detection of these tumors, contributing to an increasing recognition of their prevalence. Data shows that the limited-duration prevalence of malignant bone tumors has increased significantly. This increase is from 0.00069% in 2000 to 0.00749% in 2018, indicating an increasing recognition and diagnosis of these rare tumors over time. Survival rates vary significantly by tumor type, with approximately 50–60% for osteosarcoma and around 70% for Ewing’s sarcoma, though these rates decrease with metastasis. Key risk factors identified include genetic predispositions such as Li-Fraumeni syndrome and TP53 mutations, environmental exposures like radiation, and growth patterns related to height. The review highlights the importance of early diagnosis and treatment intervention, as survival rates are significantly better for patients with localized disease compared to those with metastatic conditions. The observed variations in survival rates across different tumor types underscore the need for tailored treatment strategies. Key risk factors include genetic predispositions and environmental exposures, highlighting the need for targeted screening and ongoing research to enhance diagnostic accuracy and treatment strategies.

21 April 2023 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
MHMehrdad Hashemi
Mehrdad Hashemi
ESEisa Sabouni
Eisa Sabouni
PRParham Rahmanian
Parham Rahmanian
MEMaliheh Entezari
Maliheh Entezari
MMMahsa Mojtabavi
Mahsa Mojtabavi
STShing Cheng Tan
Shing Cheng Tan
Hepatocellular carcinoma (HCC) is considered one of the greatest challenges to human life and is the most common form of liver cancer. Treatment of HCC depends on chemotherapy, radiotherapy, surgery, and immunotherapy, all of which have their own drawbacks, and patients may develop resistance to these therapies due to the aggressive behavior of HCC cells. New and effective therapies for HCC can be developed by targeting molecular signaling pathways. The expression of signal transducer and activator of transcription 3 (STAT3) in human cancer cells changes, and during cancer progression, the expression tends to increase. After induction of STAT3 signaling by growth factors and cytokines, STAT3 is phosphorylated and translocated to the nucleus to regulate cancer progression. The concept of the current review revolves around the expression and phosphorylation status of STAT3 in HCC, and studies show that the expression of STAT3 is high during the progression of HCC. This review addresses the function of STAT3 as an oncogenic factor in HCC, as STAT3 is able to prevent apoptosis and thus promote the progression of HCC. Moreover, STAT3 regulates both survival- and death-inducing autophagy in HCC and promotes cancer metastasis by inducing the epithelial–mesenchymal transition (EMT). In addition, upregulation of STAT3 is associated with the occurrence of chemoresistance and radioresistance in HCC. Specifically, non-protein-coding transcripts regulate STAT3 signaling in HCC, and their inhibition by antitumor agents may affect tumor progression. In this review, all these topics are discussed in detail to provide further insight into the role of STAT3 in tumorigenesis, treatment resistance, and pharmacological regulation of HCC. Graphical Abstract

21 June 2023 in Environmental Research
Verified
Journal Article
Closed access
MHMehrdad Hashemi
Mehrdad Hashemi
SASahar Abbaszadeh
Sahar Abbaszadeh
MRMohsen Rashidi
Mohsen Rashidi
NANafisesadat Amini
Nafisesadat Amini
KAKasra Talebi Anaraki
Kasra Talebi Anaraki
WZWenliang Zha
Wenliang Zha

15 April 2023 in Environmental Research
Verified
Journal Article
Closed access
ATAfshin Taheriazam
Afshin Taheriazam
MEMaliheh Entezari
Maliheh Entezari
ZFZeinab Mohammadi Firouz
Zeinab Mohammadi Firouz
SHShima Hajimazdarany
Shima Hajimazdarany
MHMohammad Hossein Heydargoy
Mohammad Hossein Heydargoy
DSDongdong Sun
Dongdong Sun

8 August 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
SDSalman Daneshi
Salman Daneshi
EMEsmaeil Barkhori Mehni
Esmaeil Barkhori Mehni
MKMohammad Kamali
Mohammad Kamali
EBEshagh Barfar
Eshagh Barfar
FBFatemeh Bagher Barahouei
Fatemeh Bagher Barahouei
RRrasoul raesi
rasoul raesi
Drug-resistant tuberculosis (DR-TB) is an increasing public health concern in Iran, with multidrug-resistant tuberculosis (MDR-TB) posing significant challenges to disease control efforts. This study examines the prevalence of DR-TB in Iran from January 2000 to October 2023. A comprehensive systematic search was conducted across multiple databases, including PubMed, Scopus, Google Scholar, EMBASE, BioMed Central, and Web of Science. The search utilized specific keywords such as "drug-resistant tuberculosis," "DR-TB," "MDR-TB," "XDR-TB," "Iran," "prevalence," and "risk factors," among others. Boolean operators (AND/OR) were employed to refine the search results. Only articles published between January 2000 and October 2023 were considered for inclusion. The search strategy followed the PRISMA guidelines, and the review questions were formulated based on the PICO model. The initial search identified 750 records. After removing duplicates and screening the titles, abstracts, and full texts, a total of 9 articles that met the inclusion criteria were included in the systematic review. Between 2000 and 2023, the prevalence of MDR-TB in Iran ranged from 5.1 to 11.3% among general TB cases, increasing to 36% among retreatment cases and 18.5% in border provinces such as Sistan-Baluchestan. Retreatment patients had a sixfold higher risk of MDR-TB compared to new cases. Comorbidities such as diabetes (OR: 2.3) and HIV (OR: 3.1), along with male sex and older age, were significant contributing factors-particularly in XDR-TB cases. Despite the rising trend in drug resistance, diagnostic and laboratory limitations remain major challenges. Key risk factors include a history of previous treatment, diabetes mellitus, limited access to healthcare, and socioeconomic barriers. Diagnostic difficulties, including inadequate laboratory capacity and underutilization of molecular diagnostic tools, further complicate TB control and management. Addressing the rising prevalence of DR-TB in Iran requires urgent public health interventions, including strengthening healthcare infrastructure, improving access to diagnostic services, and implementing community-based education programs to reduce stigma and enhance treatment adherence. Without these measures, the burden of DR-TB is likely to increase, further complicating efforts to control this public health crisis.

30 August 2022 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MSMehrdokht Sadrkhanloo
Mehrdokht Sadrkhanloo
MEMaliheh Entezari
Maliheh Entezari
MRMohsen Rashidi
Mohsen Rashidi
MHMehrdad Hashemi
Mehrdad Hashemi
RRrasoul raesi
rasoul raesi
ATAfshin Taheriazam
Afshin Taheriazam